Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation
This article was originally published in The Pink Sheet Daily
NICE determination limits recommended use to severe refractory SHPT patients.
You may also be interested in...
NICE draft appraisal concludes hyperparathyroidism therapy is unlikely to be considered cost-effective.
Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.